Metabolic cardiocytoprotectors (trimetazidine and trimethylhydrazine) in geriatrics. Short review

  • Liana Kuprash D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine
  • Olena Kuprash D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine
  • Svetlana Gudarenko D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine
Keywords: metabolic cardiocytoprotectors; cardiovascular and cerebrovascular pathology; trimethylhydrazine; elderly


The review presents the clinical studies results of the effectiveness of cardiocytoprotectors, fatty acids synthesis inhibitors, trimetazidine (preductal), and trimethylhydrazine (meldonium, mildronate) in the treatment of cardiovascular disease (angina pectoris, chronic heart failure) and the central nervous system disease (dyscirculatory encephalopathy, chronic cerebral insufficiency, stroke) various ages patients. These data indicate the prospects of using these drugs in the complex therapy of cardiovascular and cerebrovascular diseases in the geriatric clinic.

Author Biographies

Liana Kuprash, D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine

DSc (Medicine), Head of the Geriatric Pharmacology Laboratory

Olena Kuprash, D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine

MD, PhD (Medicine), Department of Clinical and Epidemiological Cardiology

Svetlana Gudarenko, D. F. Chebotarev Institute of Gerontology NAMS of Ukraine, Kyiv, Ukraine

Researcher of the Laboratory of Geriatric Pharmacology


Korkushko, O. V.; Lishnevskaya,V. Yu.; Duzhak, G. V. Age features of the functional state of the endothelium of microvessels. Circulation and hemostasis 2007, 4, 5-10. (in Russian)

Korkushko, O. V.; Yaroshenko, Yu. T. Reserve capabilities of the main functions of the cardiovascular system during aging (review of literature and own research). Probl of aging and longevity 2012, 21, 2, 119-152. (in Russian)

Frolkis, V. V. Blood circulation and aging. Ed. Chebotarev, D. F. Science: Leningrad, 1984, p. 216. (in Russian)

Chebotarev, D. F. Geriatrics in the clinic of internal diseases. Health: Kyiv, 1977, p. 3021. (in Russian)

Verzar, F. Physiologie and Gerontologie. Ztschr Alter Forschung: Zürich 1971, 3, 209-214.

Bellardinelli, R. Beneficial effects of the metabolic approach in the rehabilitation of patients with heart disease. Heart and metabolism 2009, 23, 21-24. (in Russian)

Vasyuk, Yu. L.; Kulikov, K. G.; Kudyakov, O. N. Mitochondrial dysfunction in the pathogenesis of acute infarction: principles of diagnosis and therapy with mitochondrial cytoprotectors. Ross. med. news 2008, 2, 30-41. (in Russian)

Mikhin, V. P. Cardiocytoprotectors are a new trend in clinical cardiology. Archives of Internal Medicine 2011, 1, 21-28. (in Russian).

Dambrova, M.; Liepinsh, E.; Kalvvinsh, I. Mildronate: cardioprotetective action through carnitine-lowering effect. Trends Cardiovasc Med 2002, 12, 6, 275-279.

Shakhnovich, R. M. Optimization of energy metabolism in patients with ischemic heart disease. RMJ 2021, 15, 612-618. (in Russian)

Loiacono, F.; Alberti, L.; Lauretta L. et al. Metabolic therapy for heart failure. Recenti Prog Med 2014, 105, 7–8, 288–294.

Lionetti, V.; Stanley, W. S.; Recchia, F. A. Modulation fatty acid oxidation in heart failure. Cardiovasc Res 2011, 90, 2, 202-209.

Lopaschuk, G. D. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001, 12, 1, 8-11.

Tsioufis, K.; Andrikopoulos, G.; Manolis, A. Trimetazidine and Cardioprotection: Facts and Perspectives. Angiology 2014, 66, 3, 204-210.

Kantor, P. F.; Lucien, A.; Kozak, R.; Lopaschuk, G. D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86, 580–588.

Belardinelli, R. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 2007, 28, 9, 1102-1108.

Stanley, W. C.; Marzilli, M. Metabolic therapy in the treatment of ischemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 2003, 17, 133-145.

Marzilli, M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 2003, 19, 7, 661-672.

Belardinelli, R. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 2000, 19, V35-V39.

Bertomeu-Gonzalez, V.; Burgas-Mosquera, A.; Kaski, J. C. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol 2006, 98, 5A, 19J-24J.

Chazov, E. I.; Lepakchin, V. K.; Zharova, E. A.; Fitilev, S. B.; Levin, A. M.; Rumiantzeva E. G. et al. Trimetazidine in Angina Combination Therapy – the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005, 12, 1, 35-42.

Danchin, N.; Marzilli, M,; Parkhomenko, O.; Ribeiro, J. P. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 2011, 120, 59-72.

Zhilyaev, E. V.; Urzhamova, T. V.; Glazunov, A. V. et al. Clinical aspects of the use of trimetazidine (Preductal) as an antianginal drug. Terapevticheskii Arkhiv 2004, 8, 20-23. (in Russian)

Trisvetova, E. L. Rationale for the use of preductal in stable angina pectoris. Cardiology in Belarus 2017, 9, 4, 736-746. (in Russian)

Marzilli, M.; Klein, W. Efficacy and tolerability of trimetazidine in stable angina: a meta–analysis of randomized, double–blind, controlled trials. Coron Artery Dis 2003, 14, 2, 171-179.

Makolkin, V. I.; Osadchiy, K. K. Efficacy and tolerability of trimetazidine in the treatment of stable exertional angina for 8 weeks (Russian trial TRIUMPH). Cardiology 2003, 6, 18-22. (in Russian)

Ciapponi, A.; Pizarro, R.; Harrison, J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005, 4, CD003614. 10.1002/14651858.CD003614.pub2.

Sellier, P.; Broustet, J. P. Assessment of antiischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003, 3, 361-369.

Peng, S.; Zhao, M.; Wan, J.; Fang, Q.; Fang, D.; Li, K. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials. Int J Cardiol 2014, 177, 3, 780-785.

Kim, J. S.; Kim, C. H.; Chun, K. J.; Kim, J. H.; Park, Y. H.; Kim, J. et al. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol 2013, 102, 12, 915-922.

Vasyuk, Yu. A.; Shkolnik, E. L.; Kulikov, K. G. et al. Effect of Preductal MB therapy on the course of CHF in patients with stable exertional angina after acute myocardial infarction. Results of the PRIMA study. Heart failure 2009, 10, 1, 34-36. (in Russian)

Gunes, Y.; Guntekin, U.; Tuncer, M.; Sahin, M. The effects of trimetazidine on heart rate variability in patients with heart failure. Arq Bras Cardiol 2009, 93, 2, 154-158.

Nedoshivin, A. O.; Kutuzova, A. E.; Nesterova, I. V. et al. Trimetazidine in the correction of chronic heart failure in patients with coronary heart disease. Cardiology 2002, 3, 12-15. (in Russian)

Novikova, M. V.; Glezer, M. G. Antianginal and antiischemic efficacy of trimetazidine depending on the age of patients with stable angina. Clinical gerontology 2013, 1-2, 27-33. (in Russian)

Syrkin, A. L.; Lepakhin, V. K.; Fitilev, S. B. et al. Trimetazidine for stable exertional angina in patients over 65 years of age. TRIMER study (Trimetazidine in Elderly People). Cardiology 2002, 6, 24-31. (in Russian)

Vitale, C.; Wajngaten, M.; Sposato, B.; Gebara, O.; Rossini, P.; Fini, M. et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004, 25, 20, 1814-1821.

Gurevich, M. A. Drug treatment of an elderly patient with myocardial infarction. Cjns Med 2003, 12. (in Russian)

Xu, X.; Zhang, W.; Zhou, Y.; Zhao, Y.; Liu, Y.; Shi, D. et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind at 2-year follow-up. Clin Drug Investig 2014, 34, 4, 251-258.

Khrystoforova, A. M.; Yena, L. M. Optimization of coronary heart disease treatment in hypertensive elderly patient: influence of metabolic therapy with trimetazidin. Universum 2014, 12, 13. URL: (in Russian)

Ignatenko, I. V.; Pirogov, A. L.; Altman, D. A.; Prazdnov, A. S.; Vereina, N. K. Trimetazidine in chronic heart failure patients aged above 75 years. Cardiovascular Therapy and Prevention 2006, 5, 8, 52-59. (in Russian)

Kalvinsh, I. Ya. Mildronate – mechanism of action and prospects for its use. Grindeks: Riga, 2002, p. 39. (in Russian)

Skarda, I.; Klincare, D.; Dzerve, V. et al. Modulation of myocardial energy metabolism with mildronate - an effective approach in the treatment of chronic heart failure. Proceedings of the Latvian Academy of Sciences 2001, 55, 2-3, 73-79.

Dzerve, V. Ya.; Kalvinsh, I. Ya. Mildronate in cardiology. Grindeks: Riga, 2013, p. 69. (in Russian)

Dambrova, М.; Makrecka-Kuka, М.; Vilskersts, R.; Makarova, E.; Kuka, J.; Liepinsh, E. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacol Res 2016, 113, 771-780.

Kutishenko, N. P.; Dmitrieva, N. A.; Lukina, Y. V.; Kozireva, M. P.; Semyonova, Y. E.; Deev, A. D.; Martsevich, S. Y. Influence of mildronate on the efficiency of antianginal therapy in patients with stable burden angina. Rational Pharmacotherapy in Cardiology 2005, 2, 37-42. (in Russian)

Sergienko, I. V.; Malakhov, V. V.; Naumov, V. G. Antianginal and anti-ischemic efficacy of Mildronate in the complex treatment of patients with coronary artery disease with stable angina pectoris. Atmosphere 2005, 2, 43-45. (in Russian)

Dzerve, V.; MILSS I Study Group. A dose-dependent improvement in exercise tolerance in patients with stable angino treated with mildronate. A clinical trial “MILSSI”. Medicina (Kaunas) 2011, 47, 10, 544-551.

Dzerve, V.; Matisone, D.; Pozdnyakov, Y.; Oganov, R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. Sem Cardiovasc Med 2010, 16, 3, 1-8.

Statsenko, M. E,; Starkova, G. V.; Govorukha, O. A.; Burlay, S. V.; Sporova, O. E.; Belenkova, S. V. Mildronate in complex chronic heart failure manD agement among patients in early postDinfarction period. Russian Journal of Cardiology 2005, 6, 62-66. (in Russian)

Karpov, R. S.; Koshelskaya, O. A.; Vrublevsky, A. V. et al. Clinical efficacy and safety of mildronate in the treatment of chronic heart failure in patients with coronary heart disease. Cardiology 2000, 6, 69-74. (in Russian)

Kucherenko, O. D.; Raginskiy, I. O. Antiarrhythmic effect of mildronate in patients with coronary artery disease and type 2 diabetes. Vrachebnaya praktika 2003, 4, 54-59. (in Russian)

Damulin, I. V.; Koberskaya, N. N.; Antonenko, L. M. The effect of Mildronate on cognitive impairment in dyscirculatory encephalopathy: a clinical and electrophysiological study. Neurological journal 2006, 1, 45-50. (in Russian)

Dzyak, L. A.; Golik, V. A. Application of Mildronate in the treatment of patients with dyscirculatory encephalopathy against the background of stenosing lesions of the main arteries of the head. Vrachebnoe delo 2003, 5, 6, 98-101. (in Russian)

Gafurov, B. G.; Alikulova, N. A.; Khodjaeva, N. A. Optimization of neuroprotective therapy of ischemic cerebral stroke using mildronate. Neurology 2003, 2, 27-29. (in Russian)

Suslina, Z. A.; Maksimova, M. Yu.; Kistenev, B. A.; Fedorova, T. N. Neuroprotection in ischemic stroke: the effectiveness of Mildronate. Pharmateka 2005, 13, 99-103. (in Russian)

Zhu, Yi.; Zhang, G.; Zhao, J.; Li, D.; Yan, X.; Liu, J. et al. Efficacy and safety of mildronate for acute ischemic stroke: A randomized, double-blind, active-controlled phase II multicenter trial. Clinical Drug Investigation 2013, 33, 755-760.

Evseeva, M. E.; Nikulina, G. P.; Rostovtseva, M. V. The use of metabolic drugs in the main cardiovascular pathology in patients of different ages. Polyclinic 2008, 4, 72-75. (in Russian)

Shabalin, A.; Ragino, Yu.; Liubimtseva, S.; Polonskaia, Ia.; Ivanova, M. Effect of cytoprotection on the oxidative processes and endothelial function in elderly patients with ischemic heart disease. Uspekhi gerontologii 2006, 19, 3, 116-119. (in Russian)

Kalvinsh, I.; Visokinskas, A.; Bagdonas, G.; Knasene, Iu.; Lesaukaite, V.; Matsiyauskene, Iu. Mildronate in geriatric patients with cardiac failure. Terapevticheskii Arkhiv 2006, 78, 9, 75-77. (in Russian)

Geichenko, V. P.; Kuriata, A. V.; Muzhchil, O. V.; Miroshnichenko, N. B. Indicators of humoral regulation in the dynamics of treatment of patients with heart failure by means of basic therapy and with the inclusion of the metabolic drug mildronate. Circulation and haemostasis 2004, 1, 1-3. (in Russian)

Nedogoda, S. V.; Statsenko, M. E.; Turkina, S. V.; Tyshchenko, I. A.; Poletaeva, L. V.; Tsoma, V. V. et al. Mildronate effects on cognitive function in elderly patients with arterial hypertension. Cardiovascular Therapy and Prevention 2012, 11, 5, 33-38. (in Russian)

Statsenko, M. E.; Nedogoda, S. V.; Turkina, S. V.; Tyshchenko, I. A.; Poletaeva, L. V.; Chumachok, E. V.; et al. Mildronate potential for correcting cognitive dysfunction in elderly patients with arterial hypertension. Russian Journal of Cardiology 2011, 4, 91-95. (in Russian)

Shishkova, V. N.; Malyukova, N. G.; Tokareva, R. B.; Sayutina, E. V.; Kapustina, L. A.; Osychenko, M. E. Evaluation of the efficacy of Mildronate in elderly patients with ischemic stroke. Nervous diseases 2002, 2, 36-41. (in Russian)

How to Cite
Kuprash, L., Kuprash, O., & Gudarenko, S. (2022). Metabolic cardiocytoprotectors (trimetazidine and trimethylhydrazine) in geriatrics. Short review. Ageing and Longevity, 3(2), 63-70. Retrieved from

Most read articles by the same author(s)